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Abstract
Background: Drug resistance is a major problem in cancer chemotherapy. Acquisition of chemo-
resistance not only reduces the effectiveness of drugs, but also promotes side effects and markedly
reduces the patient's quality of life. However, a number of resistance mechanisms have been
reported and are thought to be the reason for the difficulties in solving drug-resistance problems.
Result: To investigate the mechanisms of drug resistance, a set of cell lines with different levels of
sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was
established from a colorectal cancer cell line. The expression of thymidylate synthase, orotic acid
phosphoribosyltransferase and dihydropyrimidine dehydrogenase, which are well known to be
related to drug resistance, differed among these cell lines, indicating that these cell lines acquired
different resistance mechanisms. However, swainsonine, an inhibitor of N-glycan biosynthesis,
reduced 5-FU-tolerance in all resistant cells, whereas the sensitivity of the parental cells was
unchanged. Further analysis of the N-glycan profiles of all cell lines showed partial inhibition of
biosynthesis and no cytotoxicity at the swainsonine dosage tested.
Conclusion: These observations suggest that N-linked oligosaccharides affect 5-FU resistance
more widely than do drug-resistance related enzymes in colorectal cancer cells, and that the N-
glycan could be a universal target for chemotherapy. Further, swainsonine may enhance the
performance of chemotherapy by reducing tolerance.
Background
Colorectal cancer has one of the highest incidences
among all forms of cancer around the world. In many
cases, the cancer cannot be completely controlled by sur-
gical intervention, so multidisciplinary treatment includ-
ing chemotherapy is required. However, cancer cells often
Published: 21 September 2007
Molecular Cancer 2007, 6:58 doi:10.1186/1476-4598-6-58
Received: 22 June 2007
Accepted: 21 September 2007
This article is available from: http://www.molecular-cancer.com/content/6/1/58
© 2007 Hamaguchi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2007, 6:58 http://www.molecular-cancer.com/content/6/1/58
Page 2 of 9
(page number not for citation purposes)
acquire drug resistance during treatment and a patient's
prognosis can become very unfavorable [1]. Acquisition
of chemo-resistance not only reduces the effectiveness of
drugs, but also promotes side effects and markedly
reduces the patient's quality of life.
5-fluorouracil (5-FU), a fluorinated pyrimidine, is a key
anti-colorectal cancer drug. 5-FU affects the synthesis and
repair of DNA and RNA processing in cancer cells [2-4]. 5-
FU metabolic enzymes, such as thymidylate synthase
(TS), orotic acid phosphoribosyltransferase (OPRT), urid-
ine phosphorylase (UP), dihydropyrimidine dehydroge-
nase (DPD), and pyrimidine nucleoside phosphorylase
(PyNPase), are thought to play a role in the resistance
mechanism [5-8].
Oligosaccharides on glycoproteins mediate a dynamic
protein state, involving folding, quality control, secretion
and catabolism [9,10]. Glycans are also related to tumor
progression and metastasis as well as to immune system
activity [11], and their potential relationship to chemo-
resistance has recently been examined [12,13]. In N-gly-
can biosynthesis, a precursor high-mannose type oligosac-
charide, consisting of 2 N-acetylglucosamine (GlcNAc), 9
mannose (Man) and 3 glucose (Glc) residues, is synthe-
sized on a dolichol di-phosphate and transferred to a nas-
cent polypeptide in the endoplasmic reticulum. During
protein folding, one Man and three Glc residues are
removed to form an M8.1 high-mannose type N-glycan.
This oligosaccharide residue functions as a tag to carry cor-
rectly folded glycoproteins to the Golgi apparatus, while
misfolded proteins are recognized by the protein degrada-
tion system [14]. In the Golgi, α-mannosidase I removes
a further 3 Man residues from M8.1 to form M5.1, then N-
acetylglucosaminyltransferase I attaches a GlcNAc residue
to M5.1, forming the hybrid-type oligosaccharide. Next,
α-mannosidase II removes two Man residues and N-
acetylglucosaminyltransferase II adds another GlcNAc to
form complex-type N-glycans. These glycans are modified
by galactose, fucose and sialic acid residues to form a vari-
ety of oligosaccharide structures [15]. Swainsonine, a
known glycosylation inhibitor [16,17], inhibits α-man-
nosidase II activity in the N-glycan biosynthesis pathway
and blocks production of complex-type oligosaccharides
[18,19]. Swainsonine has been of great use in the study of
N-glycan functions, with many important results pub-
lished since its discovery [20-22]. The anti-tumor activity
of swainsonine has also been previously examined [23].
Swainsonine exhibits not only cytotoxicity, but inhibits
cancer cell metastasis [24,25], decreases the toxicity of
chemotherapeutic drugs [26,27] and works as immu-
nomodulator [28,29]. Despite its side effects, clinical
studies on patients have shown that swainsonine is of
some benefit as a chemotherapeutic drug [30,31], suggest-
ing that it might have further applications in this field.
Tunicamycin, which inhibits N-glycosylation, has been
shown to enhance sensitivity to cisplatin [32] and reduce
drug-resistance in multidrug-resistant carcinoma cells
[33].
We established various gradations of 5-FU resistant cell
lines from a mouse colon cancer cell line and analyzed the
expression enzymes related to resistance, the effect of
swainsonine and the glycoforms present in those cells.
Results
Establishment of 5-FU resistant murine colorectal cell lines
We established various gradations of 5-FU resistant cell
lines from the mouse colon cancer cell line, colon 26. The
morphology of the 5-FU resistant cells was similar to that
of the parental line, and their proliferation rates were sim-
ilar except for L0-500, which proliferated slightly more
rapidly and aggregated more easily, resulting in cell death
(data not shown).
Drug resistance in the parental L0 line and in the L0-200,
L0-500 and L0-1000 lines was assayed using cytotoxicity
assay and growth inhibition assay. Fifty percent inhibition
concentration (IC-50) values of the L0, L0-200, L0-500
and L0-1000 lines against 5-FU were 0.110, 1.07, 3.87 and
4.86 μg/mL, respectively, by Mossman's 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assay (Fig. 1a). To estimate the effect of growth
inhibition, we employed an alternative cytotoxicity assay,
the collagen gel droplet-embedded culture drug sensitivity
test (CD-DST) assay. IC-50 values of the L0, L0-200, L0-
500 and L0-1000 lines using this assay were 0.0810,
Growth inhibition curves of L0 (colon26), L0-200, L0-500  and L0-1000 treated with 5-FU Figure 1
Growth inhibition curves of L0 (colon26), L0-200, L0-
500 and L0-1000 treated with 5-FU. a, Cytotoxic effect 
of 5-FU was estimated by MTT assay. b, Cell growth inhibi-
tory effects of 5-FU were estimated by CD-DST. Means of 
L0, L0-200, L0-500 and L0-1000 are represented by open cir-
cles, open triangles, closed circles and closed triangles, 
respectively, the range of S.D. from 6 measurements is indi-
cated by vertical bars
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0.970, 2.20 and 2.30 μg/mL (Fig. 1b), respectively. After
maintenance for 6 months in the absence of 5-FU, the cell
lines exhibited only slightly reduced 5-FU resistance (data
not shown).
Expression of proteins related to 5-FU resistance
TS is reported to be a 5-FU catabolic enzyme, and OPRT
catalyzes 5-FU to 5-fluorouracil mono-phosphate, which
is finally taken into RNA where it inhibits RNA functions.
Thus, we used Western-blotting to measure OPRT and TS
protein levels in the resistant lines. OPRT was down-regu-
lated and TS was up-regulated in all 5-FU resistant sub-
lines; L0-200, L0-500 and L0-1000 (Fig. 2a).
As TS, OPRT, and UP expression are correlated with 5-FU
resistance, we used real-time RT-PCR to analyze the
expression of these factors in the resistant lines. TS expres-
sion was up-regulated in the 5-FU resistant cell lines,
though the change was only slight in the L0-500 line.
OPRT expression was slightly down-regulated in the 5-FU
resistant cell lines. UP expression in the L0-200 line was
up-regulated 3-fold over that in the parental line; how-
ever, its expression in the L0-500 line was the same as that
in the parental line, and it was down-regulated in the L0-
1000 line, indicating that there was no overall linear rela-
tionship between 5-FU resistance and OPRT, TS, or UP
expression (Fig. 2b). Expression of DPD, TP, and PyNPase
could not be measured, probably due to the low levels of
expression.
Effect of a swainsonine on 5-FU resistant cells
Swainsonine blocks α-mannosidase II activity, which is
necessary to convert N-glycans from hybrid-type to com-
plex-type. 5-FU resistant L0-1000 and parent cells show
the same sensitivity to swainsonine. Over 90% of cells
from both cell lines were killed by treatment with 30 μg/
mL of swainsonine, whereas 80% of cells survived at 10
μg/mL swainsonine. Therefore, we applied 5 μg/mL
swainsonine, at which concentration no cytotoxicity was
observed. Swainsonine treatment significantly reduced
the IC-50 against 5-FU of the resistant cells, but not that
of the parental L0 line (Table 1). Real-time reverse tran-
scription polymerase chain reaction (RT-PCR) showed
that expression of TS was increased in the parental cell line
and decreased in the resistant L0-1000 line by swainso-
nine treatment, whereas OPRT expression was decreased
in both lines and UP expression was not affected (Fig. 3).
N-glycan profiling
N-glycans in the resistant lines were analyzed using a 2-
dimensional mapping method combined with exogly-
cosidase digestion. Oligosaccharides were first separated
on an octadecylsilyl (ODS) column using high perform-
ance liquid chromatography (HPLC) (Fig. 4), then each
peak separated on the ODS was further analyzed on an
amide column. Oligosaccharides were assigned their
structure through a comparison of their elution positions
with those previously referenced [34] (Fig. 5). N-glycans
Table 1: Effects of swainsonine on the sensitivity to 5-FU in the 
parental and resistant sublines.
Swainsonine (-) Swainsonine (+)
IC-50 (μg/mL) Ratio IC-50 (μg/mL) Ratio
L0 (colon 
26)
0.110 1.00 0.110 1.00
L0-200 1.07 9.70 0.650 5.91
L0-500 3.87 35.1 1.45 13.2
L0-1000 4.86 44.2 3.01 27.4
IC-50s were calculated from the cell viability data obtained by MTT 
assay (n = 6).
Changes in 5-FU-related enzymes in resistant sublines Figure 2
Changes in 5-FU-related enzymes in resistant sub-
lines. a, Western blotting analyses of TS and OPRT proteins. 
b, Real-time PCR analyses of TS, OPRT, TS and UP proteins. 
mRNA expression of each enzyme is shown as the ratio rela-
tive to the parental L0 (colon 26) cell. Each column repre-
sents the mean with S.D. of 4 measurements.Molecular Cancer 2007, 6:58 http://www.molecular-cancer.com/content/6/1/58
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are classified into three types; high-mannose, hybrid and
complex, according to their terminal monosaccharides.
The ratios of glycan types were calculated and are shown
in Figure 6.
Discussion
Herein we describe a set of multistage 5-FU resistant cell
lines: L0-200, L0-500 and L0-1000. These lines are useful
in examining the mechanisms of drug resistance, as they
are of the same genetic background and utilize different
acquired mechanisms of drug resistance. The IC-50 values
of the L0-200, L0-500 and L0-1000 lines against 5-FU
were 9.7, 35 and 44 times, respectively, greater than that
of the parental L0 line by MTT assay, and the 5-FU concen-
trations in the respective cell lines were 5.4, 7.7 and 4.9
times greater than that in the maintenance media.
To analyze the mechanisms underlying 5-FU resistance,
we assayed the expression of 5-FU catabolic enzymes by
Western blotting and real-time RT-PCR. Western blotting
showed that TS expression was up-regulated whereas that
of OPRT was down-regulated in the resistant cells com-
pared to that in the parental line. This expression profile
corresponds to that in previous reports showing that TS
inactivates 5-FU, and OPRT activates 5-FU function [35-
37]. OPRT expression was correlated with the degree of
drug resistance, but TS expression in the L0-200 cell line
was stronger than that in the L0-500 or L0-1000 lines.
However, the results of real-time RT-PCR analysis did not
correspond with those of Western blotting. The expres-
sion of TS mRNA in the L0-500 cells was almost same as
that in the L0 parent cells. L0-1000 cells expressed little
OPRT protein, but OPRT mRNA was expressed at the same
level as in the L0 cells. These discrepancies might be due
to the time-lag between protein and mRNA expression
and the rate of protein degradation. Nonetheless, UP tran-
scripts were most significantly up-regulated in the L0-200
cells, but were unchanged from the parental line in the L0-
500 cells, and were down-regulated in the L0-1000 cells.
Such differential expression indicates that the respective
lines utilize different mechanisms of 5-FU resistance,
including mechanisms not analyzed in this study; e.g., the
degradation pathways of these enzymes. Such variations
in the resistance mechanisms were expected and are
thought to be the reason for the difficulties in solving
drug-resistant mechanisms experienced to date.
In our study, a low-dosage swainsonine treatment, which
shows no cytotoxicity, increased 5-FU sensitivity and
altered glycoforms in the resistant cell lines. In contrast,
the 5-FU sensitivity of the parental line was unchanged
following swainsonine treatment. N-glycan profiles of
both the resistant and parent cells were changed by swain-
sonine treatment. This result shows that swainsonine res-
cues chemotherapeutic drugs from a range of resistance
mechanisms. In all cell lines, the proportion of complex-
type N-glycans was decreased from 80% to 20% (Fig. 6),
though the continued presence of complex-type N-gly-
cans indicates that swainsonine did not block biosynthe-
sis completely. Mice are known to perish without α-
mannosidase II activity [38,39], but are able to survive
with about 20% complex-type oligosaccharides [39,40].
Therefore, monitoring of the N-glycan profile would be an
important step in the prevention of side-effects and would
increase our understanding of resistance mechanisms. In
this study, we analyzed N-glycan structures in detail in an
attempt to determine diagnostic oligosaccharide struc-
tures related to drug-resistance. We could not confirm any
common resistance-related structural characteristics in the
oligosaccharides, but clearly observed that the mecha-
nisms of 5-FU resistance were affected by alterations in the
N-glycan structure. Recently, it has been reported that
tunicamycin enhances the therapeutic effect of drugs in
multi-resistant cancer cells [33]. Tunicamycin inhibits N-
glycosylation and affects the protein folding process in the
endoplasmic reticulum, whereas swainsonine takes effect
after the completion of this process. A comparison of the
mechanisms by which these two inhibitors enhance the
effects of chemotherapeutic drugs is necessary in the
future; however, these results confirm the potential
importance of both. It has been shown that tunicamycin
enhances the effect of several drugs in multi-drug resistant
cells. Our study indicated that swainsonine may be uni-
versally effective against a range of different mechanisms
for acquired drug-resistance, thereby simplifying the
design of chemotherapy for individual patients. No lethal
side effects have been observed in clinical trials using
Effects of swainsonine on sensitivity to 5-FU and mRNA  expression of 5-FU-related enzymes Figure 3
Effects of swainsonine on sensitivity to 5-FU and 
mRNA expression of 5-FU-related enzymes. mRNA 
expression of TS, OPRT and UP following swainsonine treat-
ment of L0 (open column) and L0-1000 (closed column) 
measured by real-time RT-PCR. Data represent the ratio rel-
ative to the parental L0 cell without swainsonine. Each col-
umn represents the mean with S.D. of 4 measurements.Molecular Cancer 2007, 6:58 http://www.molecular-cancer.com/content/6/1/58
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swainsonine, but the side-effects have outweighed the
clinical advantages to date [30,31]. Our results, however,
suggest that the administration of swainsonine can pre-
vent acquired drug-resistance through the maintaining
the effectiveness of chemotherapeutic reagents, and a
reduction in the swainsonine concentration can reduce
the side-effects caused by the treatment. Clinical studies
should be undertaken to further examine this proposed
mechanism. Studies on reducing drug-resistance have
examined MS209, a P-glycoprotein inhibitor, but found
that it was unsatisfactory in combating drug resistance
[41,42]. Swainsonine, on the other hand, can be effective
against various mechanisms of resistance and its side
effects, pharmacokinetics and biochemical responses have
been clarified in previous clinical trials [30,31]. Further,
on the basis of previous studies, swainsonine is expected
to control metastasis [24,25], decrease toxicity of drugs
[26,27] and enhance immune systems [28,29]. Thus, the
role of swainsonine as well as other glycosylation inhibi-
tors in cancer therapy should be reviewed.
Conclusion
Various gradations of 5-FU resistant cell lines acquired dif-
ferent mechanisms of 5-FU resistance; however, swainso-
nine was universally effective in increasing the sensitivity
to 5-FU of all resistant cells. This result indicates that N-
glycan biosynthesis is a better target for the prevention of
5-FU resistance, and points the way to the development of
new chemotherapeutic strategies. To date, swainsonine
has not been used as an anti-cancer drug, but this study
presents a new strategy by which a low dosage of swainso-
nine can be used to recover the effectiveness of 5-FU or
other chemotherapeutic reagents in tumors with acquired
resistance.
Methods
Establishment of 5-FU resistant cell lines
Colon 26, a murine colorectal cancer cell line [43], was
very kindly provided by Dr. Tatsuji Kataoka of The Japa-
nese Foundation for Cancer Research. Colon 26 cells were
maintained in RPMI-1640 medium (Gibco BRL, Rock-
Glycoform analyses by HPLC Figure 4
Glycoform analyses by HPLC. ODS chart pattern of L0 treated without (a) and with (b) swainsonine. Each peak corre-
sponds to N-glycans illustrated in the chart. Closed square, GlcNAc; open circle, Man; closed circle, Gal; open triangle, Fuc.
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ville, MD) supplemented with 10% heat-inactivated fetal
bovine serum (Gibco), 60 U/mL penicillin, and 30 mg/L
streptomycin (Gibco), in a humidified 5% CO2 incubator
at 37°C. To establish resistant lines, 5-FU (Kyowa Hakko
Kogyo Co., Ltd., Tokyo, Japan) was added to the culture
medium at an initial concentration of 25 ng/mL. Surviv-
ing cells were harvested and seeded onto another dish
with 5-FU-containing media [44]. The concentration of 5-
FU was increased every few weeks. The parental line was
named "L0", and the 5-FU resistant lines were identified
on the basis of the 5-FU concentration (ng/mL): for exam-
ple, a line maintained in 200 ng/mL 5-FU was designated
L0-200. Four lines, L0, L0-200, L0-500 and L0-1000, were
established and the results are reported herein.
Cytotoxicity (cell death) assay
Drug resistance was measured using MTT assay [45]. All
cells were grown in RPMI-1640 medium supplemented
with 20% heat-inactivated fetal bovine serum, 60 U/mL
penicillin, and 30 mg/L streptomycin (Gibco), in a
humidified 5% CO2 incubator at 37°C. A 50 μL suspen-
sion of 1.0 × 103 cells in culture medium was plated onto
each well of a 96-well plate, and pre-incubated for 24 h.
Then, 50 μL of medium including 5-FU was added and
incubated for 70 h. Subsequently, 50 μg MTT (DOJINDO,
Kumamoto, Japan) in PBS was added to a final concentra-
tion of 5 μg/mL and incubated for 2 h. After removal of
the medium, cell membranes were permeabilized by the
addition of 100 μL of dimethyl sulfoxide per well, and
MTT formazan released from cells was measured by
absorbance at 490 and 650 nm. Cytotoxicity was evalu-
ated from the IC-50 value calculated using Origin 6.1J
software (LightStone Co. Ltd., Tokyo, Japan).
Growth inhibition assay
To verify drug resistance, we employed an alternative CD-
DST method [46]. A collagen solution was made using a
collagen gel culture kit (Nitta Gelatin Inc., Osaka, Japan)
and 30 μL of cell suspension at 2 × 104 cells/mL was added
to 30 μL of the collagen solution, drops were hung in 6-
well culture plates, and the plates were then placed in a
5% CO2 incubator at 37°C for 1 h to form a gel. Three ml
of culture medium was added to each well. After preincu-
bation for 24 h, 5-FU was added. After an additional 24 h,
each well was washed twice with 4 mL of PBS by gentle
shaking in the incubator for 10 min. After removal of the
PBS, 4 mL of culture medium was added to each well, and
cells were cultured for 6 days. Neutral red was then added
to each well at 50 μg/mL. Cells were fixed 45 min later
with 10% neutral-buffered formalin and washed with
N-glycan profiles from parental and resistant sublines treated without (a) and with (b) swainsonine Figure 5
N-glycan profiles from parental and resistant sublines treated without (a) and with (b) swainsonine. L0 (closed 
column), L0-200 (open column), L0-500 (shaded column) and L0-1000 (striped column). Code numbers of oligosaccharide 
structures described in the reference [34].Molecular Cancer 2007, 6:58 http://www.molecular-cancer.com/content/6/1/58
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water for 10 minutes. Finally, collagen gel droplets were
air-dried and quantified by Primage® (Nitta Gelatin) using
an imaging apparatus.
Swainsonine treatment
Swainsonine (Sigma) was added at 5 μg/mL to the
medium when cells were harvested, and cells were incu-
bated with the inhibitor for 5 days prior to the MTT assays,
real-time RT-PCR, and glycoform analysis. Real-time RT-
PCR was undertaken with the L0 and L0-1000, and the
data were analyzed as the ratio of transcript levels derived
from swainsonine-treated cells to those from untreated
cells.
Western blotting
Antibodies against OPRT and TS were provided by Taiho
Pharmaceutical Co., Ltd (Tokyo, Japan). Protein was
extracted from 1 × 106 cells of each line using CelLytic/
Extraction Reagent (SIGMA), and 1.5 μg of protein, meas-
ured using the Bio-Rad DC protein assay kit (Hercules,
CA), was loaded on a polyacrylamide gel (Daiichi Pure
Chemicals Co., Ltd., Tokyo, Japan) and subjected to SDS-
PAGE. After blotting, PDVF membranes were blocked
with a blocking buffer composed of PBS with 5% skim
milk and 0.001% Tween. Membranes were then washed 3
times with a washing buffer consisting of PBS plus
0.001% Tween. OPRT and TS primary antibodies were
diluted 1:500 (50 ng/mL) and 1:1000 (0.6 μg/mL) in PBS,
respectively. After overnight incubation, membranes were
washed 3 times with washing buffer and then incubated
with anti-rabbit IgG antibody as the secondary antibody
included in the ECL Plus Western blotting detection kit
(GE Healthcare UK Ltd., Buckinghamshire, England),
according to the manufacturer's instructions. After the sec-
ond antibody reaction, bands were detected using the ECL
Plus Western blotting detection kit (GE Healthcare UK
Ltd.), according to the manufacturer's instructions.
mRNA quantification
Real time RT-PCR was performed using a LightCycler™
(Roche Diagnostics K.K., Tokyo, Japan) with a QuantiTect
SYBR Green PCR Kit (Qiagen K.K.). Total RNA was iso-
lated from each cell line with ISOGEN (Nippon Gene,
Tokyo, Japan), following the manufacturer's directions.
Five μg of total RNA was used with ReverTra Ace (Toyobo
Co., Osaka, Japan) for reverse transcription. The reaction
mixture included 50 ng total RNA. We assayed the expres-
sion of OPRT, DPD, TS, thymidine phosphorylase (TP)
and UP, the murine homologue of human PyNPase.
Primer sequences were as follows: β-actin sense 5'-
GCTCTTTTCCAGCCTTCCTT-3' and antisense 5'-TCTC-
CTTCTGCATCCTGTCA-3'; DPD sense 5'-GACT-
GAAAGCTGATGGCACA-3' and antisense 5'-
TGAATAGCGCTGCATACCTG-3'; OPRT sense 5'-
TCCCGAGTAAGCATGAAACC-3' and antisense 5'-
TTAGCCGCTGCAAGTATTCC-3'; TS sense 5'-TCTGCT-
CACAACCAAACGAG-3' and antisense 5'-GCAGAAAATC-
CCAAGCTGTC-3'; UP sense 5'-
TGCTCCAACATCACCATCAT-3' and antisense 5'-ACT-
GCACCAACTCCTGAACC-3'; and TP sense 5'-TGT-
TAAGTTTGGGGGAGCTG-3' and antisense 5'-
TCTTCCACCTCCAGGGTATG-3'.
Real-time RT-PCR cycles started with 15 min at 95°C and
then 50 cycles of 15 sec at 94°C, 20 sec at 56°C and 20 sec
at 72°C for β-actin, OPRT, TS and UP. Expression levels of
each enzyme were expressed as ratios relative to β-actin
expression and compared among cell lines using the L0
parental line as a control.
Glycoform analysis
Heated and lyophilized cells (1.0 × 106 cells) were sus-
pended in 0.1 M Tris-HCl buffer (200 μL, pH 8.0) con-
taining 200 μg each of trypsin and chymotrypsin (Sigma-
Aldrich Co., St Louis, MO), incubated for 24 h at 37°C,
and then heated at 90°C for 10 min to stop enzymatic
reactions. N-glycans were released from glycopeptide-con-
taining digests by treatment with N-glycosidase F (20 U,
Roche Diagnostics, Tokyo, Japan) for 24 h at 37°C in the
same solution. Finally, pronase (200 μg, Calbiochem,
Merck, Darmstadt, Germany) was added to the crude mix-
ture and incubated for 24 h at 37°C. Oligosaccharides
were purified on a Bio-Gel P-4 column (1.0 × 38 cm, Bio-
Rad) with water as the eluant, and sugar-containing frac-
tions were collected and lyophilized. Oligosaccharides
were reductively aminated with 2-aminopyridine in the
presence of sodium cyanoborohydride (Sigma-Aldrich
Composition of N-glycans in parental and resistant sublines  treated with or without swainsonine Figure 6
Composition of N-glycans in parental and resistant 
sublines treated with or without swainsonine. Swain-
sonine-treated L0, L0-200, L0-500 and L0-1000 are shown as 
L0 SW, L0-200SW, L0-500SW and L0-1000SW, respectively. 
Forms of N-glycans; high mannose (open column), hybrid 
(striped column) and complex (closed column).Molecular Cancer 2007, 6:58 http://www.molecular-cancer.com/content/6/1/58
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Co.), according to the method of Hase et al. [47,48]. Pyri-
dylaminated (PA)-oligosaccharides were purified by gel-
filtration on a Sephadex G-15 column (Amersham Bio-
sciences, Piscataway, NJ) with 10 mM ammonium bicar-
bonate as the eluant. Sialic acid residues at the non-
reducing termini were selectively released from oligosac-
charides by acid hydrolysis at pH 2.0 and 90 °C for 60
min. PA-oligosaccharides were further purified by high
performance liquid chromatography (HPLC) (7000
series, Hitachi-High-Technologies Co, Tokyo, Japan) on
an amide column (4.6 × 250 mm, TOSOH, Tokyo, Japan).
Elution was performed at a flow rate of 1.0 mL per minute
at 40°C using two solvent systems composed of 3% acetic
acid-triethylamine buffer (pH 7.3) and acetonitrile [A,
35:65 (v/v) and B, 65:35 (v/v)]. The column was initially
equilibrated with solvent A, and 7 min after sample injec-
tion the eluant was changed to solvent B. Chromatogra-
phy was monitored by a fluorescence spectrometer
(Excitation 320 nm and Emission 400 nm).
Purified PA-oligosaccharides were analyzed by their elu-
tion positions on reverse-phase column chromatography
(HRC-ODS, 6 × 150 mm, Shimadzu Co, Kyoto, Japan).
Each oligosaccharide fraction separated by ODS liquid
chromatography was subsequently subjected to analysis
on an amide-adsorption column (Amide-80, 4.6 × 250
mm). Products in some peaks were digested with exo-gly-
cosidases and further analyzed using HPLC. As a result,
their structures were derived by matching the elution posi-
tion with the database [34,49].
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